Company overview

Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities. Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMabTM mice), and in vivo/in vitro preclinical validation studies. Biocytogen collaborates with more than 70% of the top 50 pharmaceutical and biotechnology companies worldwide. Together, we discover innovative medicines for a better, healthier world.
Founded in 2009
Waltham, Massachusetts, USA
185 employees (12 in marketing)
27% recommend to a friend
29% positive business outlook

Salaries

Help build salary transparency at Biocytogen

Share your compensation anonymously to see full data.

Contribute

People

Hiring activity

Open marketing jobs over time

4 open now

Headcount trend

Company growth over the last 12 months

Headcount +22.5% year over year

Funding

Total funding

$335.2M

Last raise

$49.8M

Post IPO Equity, 4 years ago

Funding history

Aug 2022

Post IPO Equity Biocytogen · $49.8M

Jun 2021

Series E Biocytogen

Sep 2020

Series D Biocytogen · $143M

Aug 2019

Series D Biocytogen · $77.1M

Apr 2018

Series C Biocytogen · $65.3M

Jan 2017

Series B Biocytogen

Audience

Monthly website visitors
17.6K
Month over month-2.6%
Quarter over quarter-2.8%
Top sourceSearch (48.1%)
Ad budget per month$960.5
Average search rank42.6
Traffic source mix
Search
48.1%
Direct
38.9%
Referral
6.8%
Social
5.3%
Paid referral
0.7%

LinkedIn followers

Follower count and growth

Total followers

20.7K

12-mo growth

+68.2%

Monthly growth

+5.1%

News

Links